All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study

Cyrille Touzeau,1,2,3 Aurore Perrot,4 Murielle Roussel,5 Lionel Karlin,6 Lotfi Benboubker,7 Caroline Jacquet,8 Mohamad Mohty,9 Thierry Facon,10 Salomon Manier,10 Marie-Lorraine Chretien,11 Mourad Tiab,12 Cyrille Hulin,13 Xavier Leleu,14 Hervé Avet Loiseau,4 Thomas Dejoie,9 Lucie Planche,15 Michel Attal16 and Philippe Moreau1,2

1Service d'Hématologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes; 2CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, Nantes; 3Site de Recherche Intégrée sur le Cancer (SIRIC) «ILIAD», INCA-DGOS-INSERM 12558, Nantes; 4CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse; 5Hématologie Clinique et Thérapie Cellulaire, CHU Limoges; 6Hôpital Lyon Sud, Pierre-Benite; 7Service Hématologie et Thérapies Cellulaires, CHRU Bretonneau, Tours; 8Service d'Hématologie, CHU Nancy, Vandoeuvre-lès-Nancy; 9Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint Antoine, Sorbonne Université, INSERM UMRs 938, Paris; 10Maladies du Sang, CHRU de Lille, Lille; 11Hématologie Clinique, CHU Dijon Bourgogne, Dijon; 12Service d'Hématologie, Centre Hospitalier Departemental, La Roche sur Yon; 13Service d'Hématologie, Hôpital Haut-Lévêque, CHU de Bordeaux, Pessac; 14Service d'hématologie, CHU de Poitiers, Portiers; 15Service de Biochimie, CHU Hotel Dieu, Nantes and 16Département de Recherche Clinique, CHU Hotel Dieu, Nantes, France.

Correspondence: CYRILLE TOUZEAU - cyrille.touzeau@chu-nantes.fr
https://doi.org/10.3324/haematol.2021.280394
IRD, ixazomib, lenalidomide, dexamethasone; IR, ixazomib, lenalidomide; dexamethasone

* Key inclusion criteria were: 65 years of age or younger, newly diagnosed MM with measurable paraprotein in the serum (≥ 0.5 g/dL) or urine (> 0.2 g/24 hours), transplant-eligible, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2, and adequate renal function. Key exclusion criteria were: HIV, HBV, HCV positivity, history of other malignancy (other than basal cell carcinoma and carcinoma of the cervix in situ), grade ≥2 peripheral neuropathy
Figure 1: Patient disposition

Screening

IRD induction (3 cycles) (n=42)

Transplant (n=37)

IRD (early) consolidation (2 cycles) (n=37)

IR (late) consolidation (6 cycles) (n=37)

Ixazomib maintenance (1 year) (n=31)

Completed maintenance (n=24)

5 discontinued during induction:
1 Toxicity
3 Disease progression
1 withdrew consent

6 discontinued during late consolidation:
2 Toxicity
2 Disease progression
2 withdrew consent

7 discontinued during late consolidation:
3 Toxicity
2 Progressive disease
1 investigator decision
1 withdrew consent